Tonghua Dongbao Pharmaceuticals Launches Phase III Clinical Trial for Semaglutide Biosimilar in China
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the commencement of a...
Company
Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program
China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA...
Pfizer Enters Multi-Year R&D Collaboration with Telescope Innovations to Leverage AI and Robotics
Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has entered into a multi-year collaborative...
GSK Reports Q2 2024 Earnings with 13% Growth, Vaccines Unit Sees Mixed Results
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has reported its financial results for...
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...
NICE and AstraZeneca Fail to Reach Agreement on Enhertu Reimbursement for NHS
The UK’s National Institute for Health and Care Excellence (NICE) has announced that negotiations with...
Takeda Reports 3.7% YOY Revenue Growth in Q1 2023 Fiscal Year with Priority Products Driving Sales
Japan-based multinational Takeda (TYO: 4502) has released its financial report for the fiscal year 2023...
BioNTech’s mRNA Cancer Immunotherapy BNT111 Achieves Primary Endpoint in Phase II Trial
Germany-based BioNTech SE (NASDAQ: BNTX) has announced that its mRNA cancer immunotherapy BNT111, in combination...
Pfizer Inc. Reports Q2 2024 Earnings with First Positive Growth Since Q4 2022 Peak
Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has announced its financial results for...
Merck’s Q2 2024 Earnings Miss Estimates as China Market Downturn Surprises
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has reported its financial results for the...
FibroGen Inc. Enters Restructuring Mode After Late-Stage Trial Failures for Pamrevlumab
US-based biotechnology company FibroGen Inc. (NASDAQ: FGEN), which maintains significant operations in China, is initiating...
National Comprehensive Cancer Network Renews Partnership with Medlive for Oncology Guidelines Access in China
The National Comprehensive Cancer Network (NCCN), a leading non-profit academic organization in the US, has...
Shenzhen-Based Synthetica Secures Initial Funding to Advance Oncolytic Bacteria Pipeline
Synthetica, a pioneering developer of live bacteria drugs based in Shenzhen, has announced the successful...
Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Receives European Commission Approval
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that its biosimilar version of Roche’s Avastin, Avzivi...
Gan & Lee Pharmaceuticals Gains Market Foothold in Algeria with Insulin Product Approvals
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company, has announced that it has...
MicroPort Scientific’s Fully Biodegradable Cardiac Stent Earns NMPA Nod
Shanghai-based medical device titan MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...
Suzhou Hanerxi Medical Secures Series B Funding to Build Asia’s Largest Pen Injector Facility
Suzhou Hanerxi Medical Device Development Co., Ltd, a specialist in pen syringe technology based in...
Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization
Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its...
Cutia Therapeutics’ CU-30101 NDA Accepted for Review by China’s NMPA
Cutia Therapeutics (HKG: 2487), a company specializing in dermatological treatments, has announced that the National...
WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...